Royal Bank Of Canada started coverage on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a report released on Thursday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $14.00 target price on the stock.
Other research analysts have also recently issued research reports about the stock. Canaccord Genuity set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the company a buy rating in a report on Tuesday, August 8th. Jefferies Group LLC reiterated a buy rating and issued a $19.00 price target (up previously from $16.00) on shares of Karyopharm Therapeutics in a report on Thursday, August 10th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a buy rating in a report on Saturday, June 24th. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a hold rating to a buy rating and set a $11.00 price target for the company in a report on Thursday, July 6th. Finally, BidaskClub upgraded shares of Karyopharm Therapeutics from a sell rating to a hold rating in a report on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $15.67.
Karyopharm Therapeutics (KPTI) opened at 11.00 on Thursday. The firm’s market cap is $518.52 million. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63. The company has a 50-day moving average of $9.28 and a 200-day moving average of $9.87.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The business’s quarterly revenue was down 95.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.84) earnings per share. Analysts predict that Karyopharm Therapeutics will post ($2.68) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics Inc. (KPTI) Earns Outperform Rating from Analysts at Royal Bank Of Canada” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/09/17/karyopharm-therapeutics-inc-kpti-earns-outperform-rating-from-analysts-at-royal-bank-of-canada.html.
Several institutional investors have recently added to or reduced their stakes in KPTI. Voya Investment Management LLC boosted its holdings in shares of Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after buying an additional 4,444 shares during the period. Tudor Investment Corp ET AL acquired a new position in Karyopharm Therapeutics during the second quarter worth $136,000. Teza Capital Management LLC acquired a new position in Karyopharm Therapeutics during the first quarter worth $169,000. Trexquant Investment LP acquired a new position in Karyopharm Therapeutics during the second quarter worth $202,000. Finally, American International Group Inc. boosted its holdings in Karyopharm Therapeutics by 20.9% during the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after purchasing an additional 2,836 shares during the last quarter. Institutional investors own 58.97% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.